Drug intelligence / Profile preview

QGB-02

Development stage: Unknown
Lead developer: QureGenAI
Modality: Small Molecules
Administration: Topical

Overview

QGB-02 is a first-in-class, non-androgenic small molecule developed by AceMapAI Biotechnology (under the QureGenAI brand) for the topical treatment of androgenetic alopecia (AGA). Discovered using the company's de novo Quantum AIDD platform, the drug is reported to match the efficacy of minoxidil at 1/20th of the concentration. Unlike many existing AGA treatments, it is non-androgenic, potentially offering a safer profile by avoiding hormonal side effects. It is currently in the early clinical stages, having reached clinical readiness following IND submission.

Beyond the preview

Go deeper on QGB-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QGB-02.

Explore the full profile